



**RSS (Regularly Scheduled Series)  
GRAND ROUNDS  
Presented by  
Yale School of Medicine**

**YaleCME**  
CONTINUING MEDICAL EDUCATION

**Department of Obstetrics, Gynecology and Reproductive Sciences**



**Peter L. Rosenblatt, MD**

Director of Urogynecology  
Boston Urogynecology Associates / Mount Auburn Hospital

**“The Future of Innovation in Pelvic  
Reconstructive Surgery”**

*There is no corporate support for this activity*  
Course Director/Host: Lubna Pal, MBBS, FRCOG, MS, FACOG

**Thursday, December 19, 2019, 4:00PM-5:00PM**  
**Brady Auditorium, 310 Cedar St**

**LEARNING OBJECTIVES:**

At the conclusion of this talk, the attendees will be able to:

1. Describe the changing regulatory process for new medical devices in the field of FPMRS;
2. Review the history of litigation involving transvaginal mesh for prolapse and stress incontinence; and
3. Identify factors that medical device companies consider when evaluating potentially innovative solutions.

**NEEDS ASSESSMENT:**

Over the last 20 years, there has been a great deal of innovation in the field of FPMRS, not only involving surgical implants, but also new methods of treating a range of common conditions, including stress incontinence and overactive bladder. There are many forces that drive innovation, including the desire to improve patient outcomes and address unmet clinical needs. Both physicians and industry play an important role in the development of new devices and techniques to treat pelvic floor disorders, but the future of innovation is being challenged by a number of external forces, including FDA decisions and mass tort litigation. As surgeons, we find ourselves at a crossroads, and which way we go depends not only on these external factors, but on our own actions. In this lecture, we will explore the history of innovation in FPMRS, and how we can have an impact on the future of our field.

**TARGET AUDIENCE**

ObGyn attending physicians, house staff/fellows, medical students, nurses, PA's, community Ob/Gyn's, residents, midwives, nurses and researchers.

**DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**ACCREDITATION:**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**CME CREDIT:**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credits<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**DISCLOSURE:**

Peter L. Rosenblatt, MD:  
Boston Scientific, Consultant and Legal Defense  
Coloplast, Consultant  
Ethicon, Legal Defense  
C.R. Bard, Legal Defense  
Hologic, Consultant  
Medtronic, Consultant

**FACULTY DISCLOSURE:**

Lubna Pal, MD:  
Flo Health, Consultant  
AMAG Advisory Board, Member  
GLG, Consultant  
Abbott Advisory Board, Member

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.